Workflow
奥浦迈: 国泰海通证券股份有限公司关于上海奥浦迈生物科技股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Zheng Quan Zhi Xing·2025-08-22 14:17

Summary of Key Points Core Viewpoint The company intends to utilize part of its temporarily idle raised funds for cash management to enhance fund efficiency and maximize shareholder returns while ensuring compliance with regulations and maintaining the intended use of the raised funds [1][7]. Group 1: Fundraising and Management - The company raised a total of RMB 1,643,705,576.40 through its initial public offering, with a net amount after expenses being RMB 1,643,705,576.40 [1][2]. - All raised funds are managed in a dedicated account, with agreements in place between the company, its subsidiaries, and the commercial banks [2]. Group 2: Cash Management Plan - The company plans to use up to RMB 70,000.00 million of temporarily idle raised funds for cash management, with a rolling usage period of 12 months [3][4]. - The investment products will include safe and liquid options such as fixed deposits and structured deposits, ensuring that these funds are not used for pledging or securities investment [4]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the cash management plan, confirming that it will not affect the normal operation of the fundraising projects [5][6]. - The supervisory board supports the plan, stating it will not harm the interests of the company or its shareholders [6]. Group 4: Compliance and Risk Management - The cash management activities are in compliance with relevant regulations and internal management systems, ensuring no change in the intended use of the raised funds [7]. - The company will implement strict risk control measures, focusing on high-security and high-liquidity investment products, while monitoring market conditions [5].